| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Adicet Bio Inc (NASDAQ: ACET)
ACET Technical Analysis
5
| As on 9th Jun 2023 ACET SHARE Price closed @ 5.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 15.13 & Strong Sell for SHORT-TERM with Stoploss of 14.14 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ACETSHARE Price
| Open | 5.73 | Change | Price | % |
| High | 5.74 | 1 Day | -0.32 | -5.64 |
| Low | 5.32 | 1 Week | -0.26 | -4.63 |
| Close | 5.35 | 1 Month | -0.55 | -9.32 |
| Volume | 484400 | 1 Year | -9.72 | -64.50 |
| 52 Week High 21.27 | 52 Week Low 5.26 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ACET Daily Charts |
ACET Intraday Charts |
Whats New @ Bazaartrend |
ACET Free Analysis |
|
|
ACET Important Levels Intraday
| RESISTANCE | 6.16 |
| RESISTANCE | 5.90 |
| RESISTANCE | 5.74 |
| RESISTANCE | 5.58 |
| SUPPORT | 5.12 |
| SUPPORT | 4.96 |
| SUPPORT | 4.80 |
| SUPPORT | 4.54 |
ACET Forecast April 2024
| 4th UP Forecast | 16.62 |
| 3rd UP Forecast | 13.01 |
| 2nd UP Forecast | 10.77 |
| 1st UP Forecast | 8.54 |
| 1st DOWN Forecast | 2.16 |
| 2nd DOWN Forecast | -0.07 |
| 3rd DOWN Forecast | -2.31 |
| 4th DOWN Forecast | -5.92 |
ACET Weekly Forecast
| 4th UP Forecast | 12.13 |
| 3rd UP Forecast | 9.96 |
| 2nd UP Forecast | 8.61 |
| 1st UP Forecast | 7.27 |
| 1st DOWN Forecast | 3.43 |
| 2nd DOWN Forecast | 2.09 |
| 3rd DOWN Forecast | 0.74 |
| 4th DOWN Forecast | -1.43 |
ACET Forecast2024
| 4th UP Forecast | 37.74 |
| 3rd UP Forecast | 27.35 |
| 2nd UP Forecast | 20.93 |
| 1st UP Forecast | 14.51 |
| 1st DOWN Forecast | -3.81 |
| 2nd DOWN Forecast | -10.23 |
| 3rd DOWN Forecast | -16.65 |
| 4th DOWN Forecast | -27.04 |
Adicet Bio Inc ( NASDAQ USA Symbol : ACET )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ACET Business Profile
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts. Address: 500 Boylston Street, Boston, MA, United States, 02116
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service